Drug Profile
Research programme: immunotherapeutics - Entest Group
Latest Information Update: 24 Jul 2019
Price :
$50
*
At a glance
- Originator Entest BioMedical
- Developer Entest Group
- Class Cancer vaccines; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; HIV infections; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral)